randomized phase II trial of two different sequences in first line chemotherapy of advanced non small cell lung cancer - ND
- Conditions
- non small cell lung cancerMedDRA version: 9.1Level: SOCClassification code 10029104MedDRA version: 9.1Level: PTClassification code 10062042
- Registration Number
- EUCTR2008-005967-33-IT
- Lead Sponsor
- AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
cito-histologically confirmed NSCLC- MALE OR FEMALE <75 YEARS- informed written consensus- adequate hematochemic function
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
concurrent chronic systemic immune therapy- radically resected disease- any investigational agent 4 weeks prior to entry-3-4 degree alergic reaction to any of the components of the treatment
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Secondary Objective: TTP, OS, TOXICITY;Primary end point(s): progression percentage;Main Objective: therapeutic activity of two different chemotherapic sequencies in first line in advanced NSCLC
- Secondary Outcome Measures
Name Time Method